TVGN on Nasdaq

Tevogen Inc.

American biological products company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerTVGN on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersWarren, New Jersey1
  • Incorporated inDE2
  • Business address15 Independence Boulevard, Suite #210, Warren, Nj 070592
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

“the Company” and “our Company” refer to Tevogen Bio Holdings Inc. and its consolidated subsidiary.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45-$26.1M in 2025+196% since 2023
-$60.0M-$40.0M-$20.0M02023: -$8.8M-$8.8M20232024: -$53.6M-$53.6M2024+506%2025: -$26.1M-$26.1M2025−51%
Net income645-$26.3M in 2025
-$80.0M-$60.0M-$40.0M-$20.0M0$20.0M2022: $4.4M$4.4M20222023: -$60.5M-$60.5M20232024: -$13.7M-$13.7M2024−77%2025: -$26.3M-$26.3M2025+91%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Research and development$11.1M$31.0M
General and administrative$15.0M$22.5M
Total operating expenses$26.1M$53.6M
Loss from operations-$26.1M-$53.6M
Interest expense, net-$195.6K-$184.0K
Merger transaction costs-$7.5M
Change in fair value of warrants$60.7K-$58.2K
Change in fair value of convertible promissory notes$48.5M
Loss on issuance of commitment shares-$890.0K
Net loss-$26.3M-$13.7M
Net loss attributable to common stockholders, basic-$26.8M-$10.3M
Net loss attributable to common stockholders, diluted-$26.8M-$10.3M
Net loss per share attributable to common stockholders, basic-$8.08-$3.50
Net loss per share attributable to common stockholders, diluted-$8.08-$3.50
Weighted-average common stock outstanding, basic3.3M shares2.9M shares
Weighted-average common stock outstanding, diluted3.3M shares2.9M shares

Compare Tevogen Inc. with another company

Leadership

Who has led Tevogen Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ben Baldanza2021
  2. Surendra K. Ajjarapu2023
  3. Ryan H. Saadi2024–now

Chair

  1. Surendra K. Ajjarapu2023

Chief financial officer

  1. Philippe J. Kurzweil2021
  2. Knuettel Francis Ii.2023
  3. Kirti Desai2024–now
2025
Board members and other officers (15)

Former names

  • Tevogen Bio Holdings Inc.Feb 16, 2024 to Jul 30, 20262
  • Semper Paratus Acquisition CorpJun 10, 2021 to Feb 15, 20242

Timeline

  1. Feb 16, 2024New chief executive Ryan H. Saadi becomes CEO10
  2. Jun 12, 2023New chief executive Surendra K. Ajjarapu becomes CEO11
  3. Nov 3, 2021New chief executive Ben Baldanza becomes CEO12

Filings

302 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 54 major events, 78 insider forms, 28 large holders, 120 other. The latest 20:

  1. Sep 30, 20268-K EDGAR
  2. Sep 16, 20268-K EDGAR
  3. Sep 16, 2026SCHEDULE 13D/A EDGAR
  4. Sep 16, 2026SCHEDULE 13D/A EDGAR
  5. Sep 16, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  6. Sep 16, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  7. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  8. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  9. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  10. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  11. Sep 15, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Sep 10, 20268-K EDGAR
  13. Aug 26, 20268-K EDGAR
  14. Aug 24, 2026S-8 EDGAR
  15. Aug 14, 202610-Q EDGAR
  16. Aug 3, 2026DEF 14A EDGAR
  17. Jul 30, 20268-K EDGAR
  18. Jul 23, 2026PRE 14A EDGAR
  19. Jul 14, 2026SCHEDULE 13D/A EDGAR
  20. Jul 10, 2026S-8 EDGAR

The 302 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 3 buys and 14 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 13, 2026Flomenberg NealSee RemarksSale501$6.40$3.2KForm 4
Mar 11, 2026Flomenberg NealSee RemarksSale452$7.26$3.3KForm 4
Mar 10, 2026Flomenberg NealSee RemarksSale19$7.75$147Form 4
Jun 9, 2025Saadi Ryan H.Chief Executive OfficerSale1,438,206$1.23$1.8MForm 4
Mar 12, 2025Flomenberg NealSee RemarksSale232,968$1.09$253.9KForm 4
Mar 11, 2025Flomenberg NealSee RemarksSale70,252$1.05$73.8KForm 4
Mar 10, 2025Flomenberg NealSee RemarksSale70,384$1.09$76.7KForm 4
Mar 7, 2025Flomenberg NealSee RemarksSale71,273$1.14$81.3KForm 4
Mar 6, 2025Flomenberg NealSee RemarksSale88,519$1.10$97.4KForm 4
Mar 5, 2025Flomenberg NealSee RemarksSale110,659$1.21$133.9KForm 4
Mar 4, 2025Flomenberg NealSee RemarksSale14,639$1.28$18.7KForm 4
Oct 17, 2024Flomenberg NealSee RemarksSale1,078,600$1.62$1.7MForm 4
Jun 12, 2024Desai KirtiChief Financial OfficerBuy3,000$0.82$2.5KForm 4
Jun 5, 2024Saadi Ryan H.Chief Executive OfficerBuy2,607$0.77$2.0KForm 4
Jul 17, 2023Corbin ERISA Opportunity Fund, Ltd.10% ownerSale2,320,000$10.68$24.8MForm 4
Jun 7, 2023Semper Paratus Sponsor LLC10% ownerSale8,988,889$1.00$9.0MForm 4
Nov 8, 2021Semper Paratus Sponsor LLC10% ownerBuy1,300,000Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 30. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC23,976$135.7K0.0%−9,272
Morgan Stanley18,809$106.5K0.0%+1,475
Aqr Capital Management LLC17,237$97.6K0.0%New
Goldman Sachs Group Inc14,163$80.2K0.0%New
Jane Street Group, LLC11,175$63.3K0.0%New
Fmr LLC9,826$55.6K0.0%−331
Russell Investments Group, Ltd.6,532$37.0K0.0%+726
Tower Research Capital LLC (TRC)1,494$8.5K0.0%+553
UBS Group AG1,083$6.1K0.0%−2,484
Vanguard Fiduciary Trust Co838$4.7K0.0%−530
GAMMA Investing LLC762$4.3K0.0%+622
Jpmorgan Chase & Co393$2.5K0.0%−86
Arax Advisory Partners401$2.3K0.0%New
Royal Bank Of Canada154$1.0K0.0%+33
Integrated Wealth Concepts LLC171$9680.0%New
Bnp Paribas Financial Markets121$6850.0%−161
Citigroup Inc61$3450.0%+18
Allworth Financial LP50$2830.0%New
Nisa Investment Advisors, LLC48$2720.0%New
Barclays PLC33$1870.0%−216
IFP Advisors, Inc29$1640.0%New
EverSource Wealth Advisors, LLC22$1240.0%New
Sterling Capital Management LLC20$1130.0%No change
Essential Partners LLC17$960.0%New
Wells Fargo & Company/mn14$790.0%−297

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40